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IMPORTANCE It is unclear how many patients treated with a direct oral anticoagulant
(DOAC) are using concomitant acetylsalicylic acid (ASA, or aspirin) and how this affects
clinical outcomes.
OBJECTIVE To evaluate the frequency and outcomes of prescription of concomitant ASA
and DOAC therapy for patients with atrial fibrillation (AF) or venous thromboembolic
disease (VTE).
DESIGN, SETTING, AND PARTICIPANTS This registry-based cohort study took place at
4 anticoagulation clinics in Michigan from January 2015 to December 2019. Eligible
participants were adults undergoing treatment with a DOAC for AF or VTE, without
a recent myocardial infarction (MI) or history of heart valve replacement, with at least
3 months of follow-up.
EXPOSURES Use of ASA concomitant with DOAC therapy.
MAIN OUTCOMES AND MEASURES Rates of bleeding (any, nonmajor, major), rates
of thrombosis (stroke, VTE, MI), emergency department visits, hospitalizations, and death.
RESULTS Of the study cohort of 3280 patients (1673 [51.0%] men; mean [SD] age 68.2 [13.3]
years), 1107 (33.8%) patients without a clear indication for ASA were being treated with
DOACs and ASA. Two propensity score–matched cohorts, each with 1047 patients, were
analyzed (DOAC plus ASA and DOAC only). Patients were followed up for a mean (SD) of
20.9 (19.0) months. Patients taking DOAC and ASA experienced more bleeding events
compared with DOAC monotherapy (26.0 bleeds vs 31.6 bleeds per 100 patient years,
P = .01). Specifically, patients undergoing combination therapy had significantly higher
rates of nonmajor bleeding (26.1 bleeds vs 21.7 bleeds per 100 patient years, P = .02)
compared with DOAC monotherapy. Major bleeding rates were similar between the
2 cohorts. Thrombotic event rates were also similar between the cohorts (2.5 events
vs 2.3 events per 100 patient years for patients treated with DOAC and ASA compared
with DOAC monotherapy, P = .80). Patients were more often hospitalized while undergoing
combination therapy (9.1 vs 6.5 admissions per 100 patient years, P = .02).
CONCLUSION AND RELEVANCE Nearly one-third of patients with AF and/or VTE who
were treated with a DOAC received ASA without a clear indication. Compared with DOAC
monotherapy, concurrent DOAC and ASA use was associated with increased bleeding and
hospitalizations but similar observed thrombosis rate. Future research should identify
and deprescribe ASA for patients when the risk exceeds the anticipated benefit.
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A cetylsalicylic acid (ASA), or aspirin, is commonly usedfor a variety of clinical indications including the pri-mary prevention of coronary artery disease (CAD),1,2
for management of stable ischemic heart disease,3 in periph-
eral arterial disease (PAD),4,5 and/or for the secondary preven-
tion of stroke after noncardioembolic stroke or transient
ischemic attack.6,7 The combination of ASA with oral antico-
agulation can be indicated for patients with certain devices
(eg, left ventricular assist devices) as well as for patients with
nonvalvular atrial fibrillation and/or venous thromboembo-
lism (VTE) who experience an acute coronary syndrome (ACS)
and/or undergo percutaneous coronary intervention (PCI).8,9
Aside from these situations and select other clinical sce-
narios, there is evidence that the combination of ASA and
an oral anticoagulant may increase bleeding, without a sig-
nificant reduction in thrombotic outcomes.10-13 Recent
guidelines14 recommend against prophylactic ASA use for pa-
tients at an increased risk of bleeding with concurrent use
of anticoagulants. With hundreds of thousands of patients15
on combination therapy with an anticoagulant and antiplate-
let medication, it is critical to develop a better understanding
of which patients treated with oral anticoagulation should
also receive ASA.
Consistent with other studies, we have previously
shown10 excess bleeding with combination ASA and warfarin
therapy in patients who do not have a clear indication for
ASA. However, it is unknown if dual therapy with ASA and a
therapeutically dosed direct oral anticoagulant (DOAC) simi-
larly increases bleeding. Based on the results of the COMPASS
trial,16 increased bleeding could be hypothesized but the
magnitude of effect for therapeutic DOACs is uncertain. Com-
pared with dual therapy with ASA and warfarin, one could
hypothesize a lower rate of bleeding in patients taking ASA
plus DOAC given the overall safer profile of DOAC medica-
tions as compared with warfarin.17 However, some studies
have reported higher rates of gastrointestinal bleeding with
DOACs as compared with warfarin.18-21 When combining
treatment doses of DOACs with ASA, it is plausible that over-
all bleeding rates could be elevated beyond those seen with
combination ASA and warfarin.
We determined the frequency of concomitant ASA use for
patients treated with DOACs for nonvalvular atrial fibrillation
or VTE in an observational practice-based setting. Further-
more, we compared the patient characteristics and outcomes
of concurrent DOAC-ASA use with DOAC monotherapy.
Methods
Study Design and Participants
A registry was created of adult patients newly starting a DOAC
(apixaban, dabigatran, edoxaban, or rivaroxaban) and of pa-
tients transitioning to a DOAC from warfarin at 4 medical cen-
ters in the state of Michigan. These data were collected as part
of the Blue Cross Blue Shield of Michigan–sponsored Michi-
gan Anticoagulation Quality Improvement Initiative (MAQI2).
This study is a collaborative of outpatient anticoagulation clin-
ics in Michigan that includes both academic and community
practices; all forms of health insurance are included.22 This
study is reported following the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) reporting
guidelines.23
For this study, data were assessed between January of
2015 and December of 2019. Included patients started DOAC
therapy either without recent anticoagulant use or in transi-
tion from warfarin therapy. For our primary analysis, patients
were excluded from our study if they had less than 3 months
of follow-up data available, a myocardial infarction (MI) within
6 months prior to DOAC initiation, and/or history of heart valve
replacement. Use of ASA was defined based on medications
assessed at the time of DOAC initiation. Patients meeting
the study inclusion criteria and not on ASA were included in
the DOAC monotherapy group while those on any dose of ASA
were included in the DOAC combination therapy group. Only
1 of the 4 centers participating in this study routinely enrolls
patients treated with DOACs in anticoagulation clinic monitor-
ing. More specifically, 1 of the 4 centers uses anticoagulant spe-
cialty pharmacists to educate patients and review DOAC pre-
scriptions for indication, drug interactions, and dosing based
on weight or renal function. Therefore, medication prescrip-
tions largely reflect the clinical practice from a wide group of
clinicians (eg, primary care, cardiology, hematology).
Data Collection and Outcome Measures
Data were abstracted from the time of DOAC initiation through
the earliest time of either DOAC discontinuation, transition to
an alternative anticoagulant, patient death, the patient being
lost to follow-up, or the end of the study period. The data col-
lection was performed by trained abstractors using standard-
ized data collection forms. Exposures and most outcomes were
verified through random chart audits that were performed by
the coordinating center (University of Michigan) to ensure that
the abstracted data matched the information contained in the
primary electronic medical record. This was done as part of rou-
tine practice of the MAQI2 registry. This study was approved
by the institutional review board at each of the participating
centers. Because of the nature of this study, a waiver of in-
formed consent was granted by the institutional review boards
at each participating center and the coordinating center.
Key Points
Question Among patients taking a direct oral anticoagulant
(DOAC) for atrial fibrillation and/or venous thromboembolism,
what are the outcomes following concurrent acetylsalicylic acid
(ASA, or aspirin) use?
Findings In this registry-based cohort study, one-third of patients
treated with DOACs were also taking ASA. Comparing 2 propensity
score–matched groups of 1047 patients without a history of heart
valve replacement or recent acute coronary syndrome, patients
treated with combination therapy had significantly higher rates of
bleeding and hospitalizations for bleeding; there was no observed
difference in thrombosis rates.
Meaning Many patients using DOAC therapy may be using
concomitant ASA, which may increase bleeding risk with uncertain
therapeutic benefit.
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The data registries were designed to require entry to key
data elements, including demographic data, DOAC dosing, and
details about any adverse events (eg, location of a bleeding
event). Through combined use of wide-ranging validation rules
during data entry and an automated program that identifies
missing information and prompts for completion and correc-
tion, there were no missing data in the variables used in the
analysis.
For each patient, comprehensive data were collected at
study enrollment. This included patient demographics, in-
cluding race as defined by the participant, as recorded in the
medical record. We also collected information on patient
comorbidities, bleeding and thrombosis risk factors, histo-
ries of bleeding or thrombosis, and concomitant medications
(including antiplatelet therapies other than ASA). Concomi-
tant medications assessed included nonsteroidal anti-
inflammatory drugs and other non-ASA antiplatelet thera-
pies. After enrollment, charts were abstracted at approximately
6-month intervals.
The primary study outcome was the rate of bleeding events
(which included any patient-reported bleeding event, regard-
less of severity). Secondary bleeding outcomes included
major bleeding as defined by the International Society on
Thrombosis and Hemostasis,24 nonmajor bleeding (defined as
any bleeding event that did not meet criteria for major bleed-
ing), emergency department (ED) visits for bleeding, and
hospitalizations related to bleeding. Major bleeding included
outcomes of fatal bleeding, life-threatening bleeding, and in-
tracranial or intraspinal bleeding. Life-threatening bleeding in-
cluded intracranial bleeding, a 5 g per dL drop in hemoglobin,
more than 4 units of blood transfused, or bleeding that re-
quired surgical intervention. Secondary thrombotic out-
comes included ischemic strokes, transient ischemic attack,
VTE, ACS/MI, ED visits for thrombosis, and hospitalizations for
thrombosis. Mortality data were also collected. A hyperten-
sion, abnormal renal/liver function, stroke, bleeding history
or predisposition, labile international normalized ratio, el-
derly, and drugs/alcohol concomitantly (HAS-BLED) score,25
modified to exclude ASA use and labile international normal-
ized ratio, and a Charlson Comorbidity Index score26 was
calculated for each patient at the time of enrollment.
Statistical Analysis
Based on clinical and demographic factors (eFigure 1 in the
Supplement), propensity scores were generated as a probabil-
ity of receiving DOAC plus ASA through a logistic regression
model. The propensity score was used to produce matched
DOAC plus ASA and DOAC groups using an optimal matching
method (1:1).27 The optimal matching selects all matches
simultaneously and without replacement to minimize the total
absolute difference in propensity score across all matches.
A standardized difference of less than 0.1 was used to indicate
a negligible difference in the covariates between the groups.
Covariates that maintained residual differences between the
groups were included in subsequent Poisson models.
After the matched cohorts were created (Table 1), we com-
pared event rates between the 2 outcome groups (DOAC plus
ASA and DOAC monotherapy) using Poisson regression. These
analyses were performed for each of our primary outcomes
listed in Table 2.
Patients with CAD, PAD, prior PCI/CABG, or remote MI
were included for the primary analysis. However, a pre-
defined subgroup analysis was performed to isolate those
patients without any CAD, PAD, prior MI, prior PCI/CABG
(eFigure 2 in the Supplement, Sensitivity Analysis 1). Given
the potential for ASA use to be dynamic, an additional sensi-
tivity analysis was performed where patients were assigned
to groups based on their enrollment medications and
patients who later stopped or started ASA were excluded
(eFigure 2 in the Supplement, Sensitivity Analysis 2). While
our initial analysis was matched based on the dose of the
DOACs, we also conducted a sensitivity analysis (eFigure 2 in
the Supplement, Sensitivity Analysis 3) where we did not
match on DOAC dose, given that DOAC dosing may change
longitudinally, with indication, and for multiple other clini-
cal factors. It was unclear how DOAC dose could affect
results. We did not match on specific DOAC drugs.
For each of the 3 sensitivity analyses outlined above, we
repeated the propensity match. We then assessed event rates
of matched cohorts generated from each unique set of inclu-
sion and exclusion criteria. A 2-sided P < .05 was considered
significant for all comparisons. All statistical analyses were
carried out using SAS version 9.4 and R 3.4.1.
Results
The study cohort consisted of 3280 patients without a clear
indication for ASA (1673 [51.0%] men, mean [SD] age of 68.2
[13.3] years). Over the study period, 1107 of 3280 (33.8%)
patients were treated with DOACs plus ASA compared with 2173
of 3280 (66.3%) patients treated with DOAC monotherapy. The
percentage of patients on combination therapy did not change
significantly over time (eFigure 3 in the Supplement). Low-
dose ASA (dose ≤100 mg) was used by 997 (90.1%) of all pa-
tients on ASA.
Two propensity score–matched cohorts of 1047 patients
were analyzed (DOAC plus ASA and DOAC only). After pro-
pensity score matching there were limited outstanding dif-
ferences between the outcome groups (Table 1; eFigure 2 in
the Supplement), which were then included in the Poisson
models.
Patients were followed up for a median (interquartile
range) of 12 (6, 30) months. As shown in Table 2, matched
patients taking DOAC plus ASA experienced more total
bleeding events compared with DOAC monotherapy (26.0
bleeds vs 31.6 bleeds per 100 patient years, P = .01). Specifi-
cally, patients on combination therapy had significantly
higher rates of nonmajor bleeding compared with those on
DOAC monotherapy. Major bleeding rates were not statisti-
cally different between the two groups (Figure 1). Major
bleeding subtypes (fatal, intracranial/intraspinal, and life
threatening) were not statistically different. Major rates of
gastrointestinal bleeding showed no statistically significant
difference but minor gastrointestinal bleeds were increased
with combination therapy (4.6 bleeds vs 3.0 bleeds per 100
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Original Investigation Research
jamainternalmedicine.com (Reprinted) JAMA Internal Medicine Published online April 19, 2021 E3
© 2021 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Henry Ford Health System User  on 05/10/2021

















Apixaban 1189 (54.7) 681 (61.5) −0.132 646 (61.7) 653 (62.4) −0.014
Dabigatran 165 (7.6) 82 (7.4) 0.007 93 (8.9) 69 (6.6) 0.092
Edoxaban 2 (0.1) 2 (0.2) 0.001 1 (0.1) 1 (0.1) 0.000
Rivaroxaban 817 (37.6) 342 (30.9) 0.133 307 (29.3) 324 (31) −0.034
DOAC doseb
Low 337 (16.0) 225 (21.0) 0.140 206 (19.7) 221 (21.1) 0.037
High 1769 (84.0) 845 (79.0) 841 (80.3) 826 (78.9)
Demographics
Age, mean (SD), y 66.3 (15.4) 72.0 (11.1) 0.421 71.9 (12.0) 71.9 (11.1) 0.002
Gender (% male) 1032 (47.6) 641 (57.9) −0.203 603 (57.6) 603 (57.6) 0.000
BMIc >30 kg/m2 1045 (49.3) 564 (52.1) −0.071 564 (53.9) 553 (52.8) 0.021
Alcohol or drug use 136 (6.3) 86 (7.8) −0.060 68 (6.5) 83 (7.9) −0.056
Tobacco use
Former 721 (33.2) 487 (44.0) −0.215 446 (42.6) 462 (44.1) −0.032
Current 189 (8.7) 81 (7.3) 0.050 70 (6.7) 77 (7.4) −0.025
Indication
AF/Aflutter 1316 (60.6) 868 (78.4) −0.383 822 (78.5) 815 (77.8) 0.015
DVT/PE 876 (40.3) 264 (23.9) 0.348 235 (22.5) 253 (24.2) −0.037
Both 19 (0.9) 25 (2.3) −0.121 10 (1.0) 21 (2.0) −0.092
Comorbidities
CAD 320 (14.7) 497 (44.9) −0.709 294 (28.1) 469 (44.8) −0.389
Cancer 483 (22.2) 280 (25.3) −0.074 258 (24.6) 267 (25.5) −0.020
CHF 318 (14.6) 291 (26.3) −0.290 230 (22.0) 273 (26.1) −0.103
Chronic liver disease 74 (3.4) 49 (4.4) −0.057 37 (3.5) 48 (4.6) −0.054
CKD 343 (15.8) 244 (22.0) −0.161 221(21.1) 234 (22.4) −0.032
Diabetes mellitus 471 (21.7) 358 (32.3) −0.265 318 (30.4) 350 (33.4) −0.069
History of falls 120 (5.5) 90 (8.1) −0.115 64 (6.1) 87 (8.3) −0.087
Hypercoagulable state 62 (2.9) 14 (1.3) 0.121 6 (0.6) 11 (1.1) −0.035
HTN 1143 (52.6) 696 (62.9) −0.229 689 (65.8) 681 (65.0) 0.016
PAD 97 (4.5) 115 (10.4) −0.242 72 (6.9) 110 (10.5) −0.140
Prior PCI/CABG 128 (5.9) 260 (23.5) −0.502 120 (11.5) 242 (23.1) −0.341
History of bleeding or thrombosisd
Bleeding, d
≤30 92 (4.2) 42 (3.8) 0.021 42 (4.0) 40 (3.8) 0.010
>30 115 (5.3) 61 (5.5) −0.018 61 (5.8) 60 (5.7) 0.004
History of embolism (not DTE/PE) 28 (1.3) 19 (1.7) −0.033 14 (1.3) 18 (1.7) −0.031
Prior
CVA/TIA 217 (10.0) 171 (15.5) −0.158 154 (14.7) 161 (15.4) −0.020
DVT/PE 232 (10.7) 106 (9.6) 0.000 98 (9.4) 103 (9.8) −0.016
GIB 126 (5.8) 72 (6.5) −0.029 71 (6.8) 69 (6.6) 0.008
Remote MI (>6 mo) 86 (4.0) 167 (15.1) −0.397 75 (7.2) 161 (15.4) −0.284
Medications
Aspirin, mg
≤100 N/A 997 (90.1) N/A N/A 948 (90.5) N/A
>100 N/A 110 (9.9) N/A N/A 99 (9.5) N/A
Estrogen/progesterone 46 (2.1) 6 (0.5) 0.139 15 (1.4) 6 (0.6) 0.074
Non-ASA antiplatelet 53 (2.4) 40 (3.6) −0.056 45 (4.3) 36 (3.4) 0.051
NSAID 94 (4.3) 39 (3.5) 0.038 32 (3.1) 38 (3.6) −0.029
(continued)
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patient years, P = .03; eTable 1 in the Supplement). Throm-
botic event rates were overall low but similar between the
groups (Figure 2). Patients were more often hospitalized on
combination therapy vs DOAC monotherapy (9.0 vs 6.5
admissions per 100 patient years, P = .02). More specifically,
hospitalizations for bleeding were higher with DOAC plus
ASA compared with DOAC monotherapy while hospitaliza-
tions for thrombotic outcomes were similar. Mortality and
ER visits for bleeding rates were similar between the 2
groups.
Sensitivity Analyses
In the first sensitivity analysis, excluding patients with any his-
tory of MI, CAD, PAD, or PCI/CABG, we compared 516 matched
pairs instead of 1047 matched pairs included in the primary
analysis. Bleeding rates were similarly elevated, but the in-
crease was no longer statistically significant (eTable 2 in the
Supplement).
In the second sensitivity analysis, excluding patients who
started or stopped ASA after study enrollment, we compared
621 matched pairs. Emergency department visits and hospi-

















Months of follow-up, median (IQR) 12 (6, 24) 12 (6, 30) 0.020 12 (6, 30) 12 (6, 30) 0.870
Other, mean (SD)
Modified HAS-BLEDe 2.0 (1.2) 2.6 (1.1) 0.451 2.4 (1.2) 2.6 (1.2) 0.123
CCI 4.0 (2.1) 5.1 (1.9) 0.522 4.8 (1.9) 5.1 (1.9) 0.129
Abbreviations: AF, atrial fibrillation; Aflutter, atrial flutter; ASA, acetylsalicylic
acid or aspirin; BMI, body mass index; CABG, coronary artery bypass graft;
CAD, coronary artery disease; CCI, Charlson Comorbidity Index; CHF, congestive
heart failure; CKD, chronic kidney disease; CVA, cerebrovascular accident;
DOAC, direct oral anticoagulant; DVT, deep vein thrombosis;
GIB, gastrointestinal bleed; HAS-BLED, hypertension abnormal renal/liver
function stroke, bleeding history or predisposition, labile international
normalized ratio, elderly, drugs/alcohol concomitantly; HTN, hypertension;
IQR, interquartile range; MI, myocardial infarction; N/A, not applicable;
NSAID, nonsteroidal anti-inflammatory drug; PAD, peripheral arterial disease;
PCI, percutaneous coronary intervention; PE, pulmonary embolism;
TIA, transient ischemic attack.
a Denominator is equal to No. at the top of the column.
b Low dose defined as a total daily dose of dabigatran <300 mg, apixaban
<10 mg, rivaroxaban <20 mg, edoxaban <60 mg. High dose is considered
a total daily dose of dabigatrain 300 mg, apixaban 10 mg, rivaroxaban
20 mg, and edoxaban 60 mg.
c Body mass index calculated as weight in kilograms divided by height in meters
squared.
d Bleeding history as assessed at the time of warfarin initiation.
e HAS-BLED score modified to exclude aspirin use.
Table 2. Outcomes of DOAC vs DOAC Plus ASA
Outcome






New thrombosis 2.30 (1.98-2.59) 2.50 (2.20-2.83) .80
Ischemic/embolic stroke 0.90 (0.71-1.08) 0.70 (0.55-0.90) .31
TIA 0.20 (0.10-0.27) 0.10 (0.05-0.20) .58
PE 0.20 (0.14-0.33) 0.20 (0.09-0.26) .67
DVT 0.40 (0.28-0.53) 0.90 (0.70-1.07) .07
MI 0.10 (0.05-0.20) 0.10 (0.02-0.12) .51
New bleed 26.00 (25.05-27.06) 31.60 (30.54-32.75) .009
Major 3.59 (3.23-3.98) 4.95 (4.52-5.41) .09
Fatal 0.06 (0.02-0.13) 0.05 (0.02-0.12) .82
Intracranial or intraspinal 0.39 (0.28-0.53) 0.33 (0.23-0.46) .75
Life threatening 1.05 (0.86-1.27) 1.42 (1.20-1.67) .38
Nonmajor 21.70 (20.77-22.60) 26.10 (25.14-27.15) .02
ED visit 11.50 (10.84-12.18) 13.80 (13.05-14.52) .14
For bleeding 10.40 (9.77-11.04) 13.00 (12.31-13.74) .08
For clotting 1.30 (1.06-1.51) 0.80 (0.65-1.02) .12
Hospitalization 6.50 (6.03-7.04) 9.10 (8.51-9.70) .02
For bleeding 5.30 (4.87-5.78) 8.20 (7.62-8.75) .006
For clotting 1.20 (1.01-1.46) 0.90 (0.75-1.14) .31
Death 3.40 (3.02-3.75) 3.80 (3.39-4.16) .76
Abbreviations: ASA, acetylsalicylic
acid or aspirin; DOAC, direct oral
anticoagulant; DVT, deep vein
thrombosis; ED, emergency
department; MI, myocardial
infarction; PE, pulmonary embolism;
TIA, transient ischemic attack.
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talizations for bleeding were significantly increased for pa-
tients treated with DOAC plus ASA (14.1 ED visits vs 10.3 ED
visits per 100 patient years, P = .04; 9.6 admissions vs 5.8 ad-
missions per 100 patient years, P = .02, respectively). Other-
wise there were no significant differences between the 2 groups
(eTable 3 in the Supplement) for other outcomes.
For the third sensitivity analysis, where DOAC dose was
not included in the propensity score match, we again com-
pared 1047 matched pairs. The findings were largely un-
changed from those of the primary analysis. However, the out-
come of all hospitalizations no longer showed a statistically
significant increase for patients receiving combination therapy.
A statistically higher rate of ED visits for clotting was ob-
served for DOAC monotherapy compared with DOAC plus ASA
(1.47 vs 0.82 ER visits per 100 patient years, P = .04, eTable 4
in the Supplement) but overall rates of thrombosis were simi-
lar to those from the primary analysis.
Discussion
In this large, registry-based cohort study of patients treated
with DOACs for AF and/or VTE, one-third of patients were tak-
ing concomitant ASA without a well-defined therapeutic in-
dication. Treatment with combination DOAC and ASA therapy
was associated with increased bleeding rates. In particular,
nonmajor bleeding was increased, as were admissions re-
lated to bleeding. Rates of thrombotic outcomes appeared simi-
lar in the 2 treatment groups.
In our sensitivity analyses limiting the study to patients
without any apparent vascular indication for ASA (eTable 1 in
the Supplement, n = 516 matched pairs) while taking a DOAC
and to patients who maintained their treatment group assign-
ment (eTable 2 in the Supplement, n = 621 matched pairs), out-
comes were similar to those of the primary analysis. Despite
lower power to detect statistically significant differences, the
point estimates in all 3 sensitivity analyses supported the find-
ings of the primary analysis. When a specific DOAC dose was
not included in the propensity score match (eTable 3 in the
Supplement), we did observe a statistically higher rate of ED
visits for thrombosis but no difference in overall thrombosis
rates, thrombosis rates by clotting subtype, and admissions for
thrombosis. This finding is of unclear clinical significance and
merits ongoing study; overall we did not observe a clear throm-
botic benefit with combination therapy.
There remains limited evidence on how to optimally
combine DOACs with ASA outside the setting of an ACS
and/or PCI procedure. The randomized OAC-ALONE trial28
evaluated oral anticoagulation with or without concomitant
antiplatelet therapy for patients with stable CAD and atrial
fibrillation. This study was terminated early due to low
patient enrollment and accordingly was underpowered to
answer this question. Additionally, only one-quarter of the
patients were prescribed DOAC therapy. The subsequent
AFIRE trial29 similarly studied patients with stable coronary
artery disease (history of PCI with stenting, CAD, or history of
CABG) and atrial fibrillation, evaluating rivaroxaban mono-
therapy compared with rivaroxaban and antiplatelet therapy.
This randomized study was conducted in Japan and was ter-
minated early due to increased mortality with combination
therapy. Rivaroxaban was noninferior for the efficacy end
point and superior for the safety end point.29 The AFIRE trial
was similar in size and results to our practice-based popula-
tion. Notable differences in our study as compared with the
AFIRE trial include no mortality difference in our population,
limiting the analysis to patients on ASA vs other antiplatelet
agents, broad DOAC medication and dose use, inclusion of
patients with VTE, and a largely White population. Therefore,
it is probable that the baseline thrombotic risk differed
between the 2 populations. Ultimately, while emerging data
seem to suggest that anticoagulant monotherapy alone may
be sufficient for some patients, further confirmation of these
findings is necessary.





































Figure reflects outcomes from propensity matched cohorts. Bleed is an
aggregate outcome including major and nonmajor bleeding. Abbreviations:
ASA, acetylsalicylic acid or aspirin; DOAC, direct oral anticoagulant;
ED, emergency department.


































Figure reflects outcomes from propensity matched cohorts. Thrombosis is an
aggregate outcome including ischemic/embolic stroke, transient ischemic
attack, pulmonary embolism, deep vein thrombosis, and/or myocardial
infarction. Abbreviations: ASA, acetylsalicylic acid or aspirin; DOAC, direct oral
anticoagulant; ED, emergency department.
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It is important to acknowledge that there are numerous pa-
tient subgroups and clinical scenarios where the role of com-
bination therapy compared with that of anticoagulant mono-
therapy has not been sufficiently studied. Examples include
patients with vascular stents, myeloproliferative neoplasms,
poorly controlled vascular risk factors, and thrombophilias. In
such scenarios, shared decision-making and individualized care
should remain standard.
We did not see a substantial decline in the number of pa-
tients on combination therapy over time (eFigure 3 in the
Supplement). This may reflect the overall lack of data on how
to optimally manage such patients, especially those with mul-
tiple vascular risk factors. The proportion of patients taking
combination DOAC plus ASA therapy, about one-third, is simi-
lar to that observed in our prior analysis of patients treated with
warfarin plus ASA.10 It is notable that about half of the pa-
tients receiving combination therapy had no apparent vascu-
lar indication to suggest a possible need to add ASA (eTable 1
in the Supplement). It is possible that such patients would
benefit from efforts to deprescribe ASA to patients on sys-
temic anticoagulation.
Strengths and Limitations
Strengths of the present study include use of real-world pa-
tients with robust statistical methods, including use of a pro-
pensity score match. We were not able to fully match on all in-
cluded variables but those with residual differences were
included in the Poisson regression models (eFigure 1 in the
Supplement). While ASA use was not randomized, the pro-
pensity score match based on numerous covariates allowed us
to reduce the impact of selection biases and compare 2 matched
groups. The study included patients with atrial fibrillation but
offers unique insight on this topic by including patients anti-
coagulated for VTE. Additionally, several sensitivity analyses
supported our study findings. The present study largely in-
cluded patients newly prescribed DOACs (745 of 1047, 71.2%)
but also included patients who switched to DOACs from war-
farin, making it generalizable to routine clinical practice. Pa-
tients were followed for relevant clinical outcomes for a me-
dian of 1 year but up to 5 years using predefined forms for data
abstraction, and random medical record audits were con-
ducted to verify data accuracy. Patients received routine an-
ticoagulation care and were managed by a spectrum of medi-
cal specialties.
Limitations of the study include those inherent to the reg-
istry design including the potential for unmeasured or uncap-
tured confounding variables. While abstractors have exten-
sive training, come largely from clinical backgrounds, and have
well defined variables to assess for, we did not specifically as-
sess interrater reliability for this study. Routine audits have not
found significant discrepancies between our registry and the
primary electronic medical record. Patients were only in the
state of Michigan. While we still believe the results are gener-
alizable, it was a geographically limited population. Use of ASA
was specifically assessed at the time of study enrollment and
some patients had been on ASA for some time prior to study
entry. While attention was given to ASA use in follow-up, it is
possible that changes in this nonprescription medication were
not well captured in the registry. The sensitivity analysis lim-
iting the study to patients who maintained their ASA use
throughout the study period supported the findings of the pri-
mary analysis (Sensitivity Analysis 2). It is possible that not all
clinical outcomes were captured, especially if patients re-
ceived their care outside our research collaborative and this
outside medical care was not subsequently documented in fol-
low-up. Therefore, the observed event rates may underesti-
mate the true event rates.
To have sufficient power to answer the study question, we
evaluated patients with both AF and VTE. While we matched
on indication for anticoagulation, it is not certain if patients with
VTE and AF have different net risk with combination therapy.
While we believe this study reflects actual clinical practice, all
of our centers are led by anticoagulation experts who regularly
engage in quality improvement activities pertaining to antico-
agulation. It is possible that this would bias the results com-
pared with other centers without these resources. Finally, the
overall rates of thrombosis and many bleeding subtypes were
low. Accordingly, this study is likely underpowered to make con-
clusions about thrombotic outcomes and outcomes of some
bleeding subtypes. It is also not able to distinguish outcomes
based on the specific type of DOAC.
Conclusions
Concurrent use of a DOAC and ASA in patients without a recent
ACS or heart valve replacement is common and associated with
increased bleeding and related hospitalization. Further research
is needed to determine if select high-risk patient subgroups de-
rive a net benefit from combination therapy. Efforts should be
made to help clinicians identify and deprescribe ASA for patients
taking a DOAC without an indication for ASA.
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